Drug delivery for large molecules and delivery vehicles
The G-blocks patented technology is based on extensive research and cumulative knowledge of mucus systems and the effects of G-blocks on the mucus barrier carried out at the Department of Biotechnology at NTNU. G-blocks are able to modify the physical properties of mucus structure thereby improving access to the plasma membrane and uptake. They decrease the density of cross links in the mucus gel altering the pore size without compromising the physiological properties of mucus. This makes G-blocks a very promising technology with an excellent chance for commercial success in the drug delivery market. The G-blocks technology is covered by a strong patent portfolio which is constantly being improved, reinforced and optimized. 35 patent applications are filed worldwide, and also 5 different technology platform patents are filed. Subsequently there has been filed additional applications to cover the world market needs for an industrial big pharma partner. The patent protected technology includes a new drug delivery method and a new drug material as well as several possible uses. Further development of the IPR portfolio will give the opportunity to file key patent applications for new possible uses and delivery methods. A thorough IPR landscape analysis has been performed showing a fast growth of new patent applications and technologies involving drug delivery. We thus have intention of building a strong patent portfolio to keep our competitive advantage. The patent portfolio is fully owned by NTNU Technology Transfer AS.
Mucus covers virtually all surfaces in the human body not covered by skin and provides a significant barrier to the delivery of drugs based on macromolecular drugs (big drugs). As mucus is abundant at all surfaces relevant for drug delivery (GI tract, lung and nasal cavities, eye, reproductive systems etc.) its properties must be considered when developing delivery technologies for macromolecules. Mucus is a unique and specialized biological material and mucosal secretions are composed primarily of glycoprotein biopolymers, mucins, which in addition to the secreted form may also be membrane bound as part of the glycoprotein coat of cells, the glycocalyx. Both forms act as barriers to entry of foreign material and therefore drug delivery. -
Project Manager:Eivind Andersen Phone: +47 900 30 570 E-mail: Eivind.Andersen@ntnu.no